EMA recommends suspension of 17-OHPC medicines in the EU
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has advised the suspension of marketing authorizations for therapeutics containing 17-hydroxyprogesterone caproate (17-OHPC) in the European Union (EU).
The recommendation follows a review that raised concerns about an as-yet unconfirmed risk of cancer in individuals exposed to 17-OHPC in the womb.
The PRAC review included a large population-based study spanning 50 years.
Despite the low number of cancer cases and limitations such as insufficient information on cancer risk factors, the committee concluded that a possible cancer risk could not be ruled out.
In addition to cancer risk concerns, new studies have indicated that 17-OHPC is ineffective in preventing premature birth.
PRAC examined a study involving more than 1,700 pregnant women with a history of preterm delivery which found that 17-OHPC did not outperform a placebo in preventing recurrent preterm births or related medical complications in newborns.
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our company profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the form below
By GlobalDataTwo published meta-analyses further confirmed the lack of efficacy in preventing preterm birth.
For other authorized uses of 17-OHPC, such as the treatment of gynecological and fertility disorders, PRAC found limited evidence of effectiveness.
The committee’s review process also included consultations with experts in obstetrics, gynecology, fertility treatment, and patient representatives.
In some EU countries, 17-OHPC medicines have been authorized as injections for preventing pregnancy loss or premature birth in pregnant women. They are also used for treating conditions related to progesterone deficiency.
In a media statement, EMA said: “In view of the concern raised by the possible risk of cancer in people exposed to 17-OHPC in the womb, together with the data on the effectiveness of 17-OHPC in its authorized uses, PRAC considered that the benefits of 17-OHPC do not outweigh its risks in any authorized use.
“The committee is therefore recommending the suspension of the marketing authorizations for these medicines. Alternative treatment options are available.”
Ethel Purdy – Medical Blogger & Pharmacist
Bridging the world of wellness and science, Ethel Purdy is a professional voice in healthcare with a passion for sharing knowledge. At 36, she stands at the confluence of medical expertise and the written word, holding a pharmacy degree acquired under the rigorous education systems of Germany and Estonia.
Her pursuit of medicine was fueled by a desire to understand the intricacies of human health and to contribute to the community’s understanding of it. Transitioning seamlessly into the realm of blogging, Ethel has found a platform to demystify complex medical concepts for the everyday reader.
Ethel’s commitment to the world of medicine extends beyond her professional life into a personal commitment to health and wellness. Her hobbies reflect this dedication, often involving research on the latest medical advances, participating in wellness communities, and exploring the vast and varied dimensions of health.
Join Ethel as she distills her pharmaceutical knowledge into accessible wisdom, fostering an environment where science meets lifestyle and everyone is invited to learn. Whether you’re looking for insights into the latest health trends or trustworthy medical advice, Ethel’s blog is your gateway to the nexus of healthcare and daily living.
